profit from every $100 of sales.
$0$100
IRadimed
$85.35+0.14% today
+1.0% in 1 year
1-year low $76.681-year high $105.15
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $48.55 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What IRadimed sold, what it kept, and what it did with the cash.
Sales went from $53.3 million in 2022 to $83.8 million in 2025, with $22.5 million of profit last year.
SalesProfit
IRadimed handed back 91% of the cash it generated last year.
$15M
Free cash flow 2025$17M
Bought back its own shares–
Paid as dividends$15M
Cash vs. debt$51M vs. $0
IRadimed vs. similar companies
IRadimed grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| IRadimed | 48.6× · Expensive | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads IRadimed's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 53 | 66 | 73 | 84 | |
| 41 | 50 | 56 | 64 | |
| 16 | 20 | 22 | 26 | |
| 16 | 21 | 23 | 27 | |
| 13 | 17 | 19 | 22 | |
| 1.02 | 1.35 | 1.50 | 1.75 | |
| 77.4% | 76.5% | 76.9% | 76.7% | |
| 29.3% | 30.6% | 30.0% | 31.2% | |
| 24.1% | 26.2% | 26.3% | 26.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 86 | 92 | 98 | 109 |
| Cash | 58 | 50 | 52 | 51 |
| Total debt | 2 | 2 | 0 | 0 |
| Total liabilities | 12 | 21 | 12 | 14 |
| 74 | 71 | 87 | 95 | |
| 13 | 13 | 13 | 13 | |
| 16.3% | 21.5% | 20.0% | 21.8% | |
| 17.4% | 24.1% | 22.2% | 23.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 10 | 13 | 26 | 25 | |
| 2 | 8 | 9 | 8 | |
| 8 | 5 | 17 | 17 | |
| Dividends paid | 13 | 13 | 14 | 15 |
| – | – | – | – | |
| 1 | 2 | 3 | 3 |
Valuation
- 48.6×
- 42.2×
- 2.46
- 12.1×
- 13.0×
- 66.0×
- 38.1×
- 1.5%
- 2.1%
- 1.3%
Profitability
- 76.7%
- 31.2%
- 26.8%
- 35.4%
- 21.4%
- 19.7%
- 24.5%
- 20.6%
- 27.3%
- 3.8%
Growth
- +16.3%
- +19.7%
- −2.5%
- –
- +0.8%
Financial health
- -1.8×
- 0.00
- 0.0%
- –
- 7.13
- 7.13
- 0.75
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 7%of 946
Top 9%of 872
Bottom 23%of 563
Top 36%of 868
Top 47%of 986
What analysts expect
- Average price target
- $120.00
- Range
- $120.00 – $120.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 1, 2026 | 0.49 | 0.42 | +16.7% |
| Feb 10, 2026 | 0.54 | 0.49 | +10.2% |
| Nov 3, 2025 | 0.47 | 0.48 | −2.1% |
| Aug 1, 2025 | 0.49 | 0.45 | +8.9% |
| May 5, 2025 | 0.42 | 0.43 | −2.3% |
| Feb 13, 2025 | 0.44 | 0.45 | −2.2% |
| Oct 31, 2024 | 0.43 | 0.39 | +10.3% |
| Aug 1, 2024 | 0.42 | 0.37 | +13.5% |
1.3%of the share price, paid each year
On $1,000 invested$13a year at today's yield, before tax
–per share
Raised1 yearin a row, in our data
Paid per share, each year
$1.00 in 2022 → $1.18 in 2025
How safe it looks
66.9% of its profit
Room to growStretchedMore than it earns: 91.0%
News
IRadimed Corporation Q3 2026 Earnings Call SummaryYahoo Finance · Oct 30, 2026Iradimed anticipates $25M-$26.5M Q4 revenue as 3870 pump output targets 50%+ sequential growthSeeking Alpha · Oct 30, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
5/7Passes 5 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
68Pass
Benjamin Graham
54No pass
Philip Fisher
80Pass
Peter Lynch
65Pass
Joel Greenblatt
25No pass
Charlie Munger
80Pass
Terry Smith
74Pass
Questions about IRadimed
Is IRadimed a good stock to buy?
A strong, very profitable business, but the price is high. 5 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the IRadimed AI analysis
What does IRadimed do?
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It is in Medical - Devices.
Does IRadimed pay a dividend?
Yes. At today's price the dividend is 1.3% a year, about 67% of its yearly profit. In 2025 it paid out $15.0 million in dividends.
Is IRadimed stock halal?
Yes. IRadimed passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has IRadimed stock done over the past year?
Up 1.0% over the past twelve months, to $85.35. It traded between $76.68 and $105.15 and is 18.8% below its high.
Who are IRadimed's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with IRadimed's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.